The management of GCA in this patient included the use of high-dose glucocorticoids and the introduction of tocilizumab, an interleukin-6 (IL-6) inhibitor that has proven effective in treating refractory GCA or GCA with a high risk of complications [17]. The gene discussed is IL6; the disease is temporal arteritis.